drugset / Trial / NCT07093814
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Timeline
- Start
- 2025-09-02
- Primary completion
- 2028-12-31
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VRT106 | Unknown | — | Intravenous |